Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
Advertisement
The patient cohort had median OS of 27 months and a five-year OS of 24.5%.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Researchers developed the score because no early risk-stratification system has been validated in this setting.
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
An imaging assessment at day 30 showed that 90% of patients had a complete response in terms of systemic disease.
With a median follow up of 41 months, the three-year PFS and OS rates were 85% and 86%, respectively.
The single-arm, phase II clinical trial enrolled 50 previously untreated patients with a median age of 69 years.
The trial assessed discontinuation of ibrutinib treatment in patients with indolent clinical forms of MCL.
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Liso-cel demonstrated high ORR and CR rate that were durable and was well tolerated.
The study included 300 patients with advanced MCL who did not have clinically significant comorbidities.
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.